ScinoPharm Taiwan, Ltd. (TPE:1789)
20.95
+0.35 (1.70%)
Mar 10, 2026, 10:25 AM CST
ScinoPharm Taiwan Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 136.95 | 339.35 | 287.06 | 353.22 | 243.47 | Upgrade
|
| Depreciation & Amortization | 516.73 | 488.28 | 461.17 | 439.47 | 381.53 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.19 | 4.64 | 0.42 | 0.76 | 0.27 | Upgrade
|
| Asset Writedown & Restructuring Costs | -2.25 | 1.12 | -0 | -0.63 | -1.38 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.32 | 9.53 | -8.67 | 2.1 | -3.91 | Upgrade
|
| Provision & Write-off of Bad Debts | -0.04 | 1.67 | -0.07 | 0.14 | 0.12 | Upgrade
|
| Other Operating Activities | 30.23 | -51.92 | -19.71 | 3.1 | -15.95 | Upgrade
|
| Change in Accounts Receivable | 21.25 | 182.33 | -152.89 | -275.16 | 26.14 | Upgrade
|
| Change in Inventory | -32.61 | -175.18 | -347.47 | 157.63 | -81.36 | Upgrade
|
| Change in Accounts Payable | -18.44 | -20.32 | -23.99 | 55.57 | -89.98 | Upgrade
|
| Change in Unearned Revenue | -4.05 | 8.43 | 43.22 | -2.81 | 3.72 | Upgrade
|
| Change in Other Net Operating Assets | -50.73 | -37.01 | -7.95 | 40.4 | 47.17 | Upgrade
|
| Operating Cash Flow | 595.91 | 750.91 | 231.13 | 773.79 | 509.82 | Upgrade
|
| Operating Cash Flow Growth | -20.64% | 224.89% | -70.13% | 51.78% | -46.13% | Upgrade
|
| Capital Expenditures | -291.29 | -280.17 | -268.43 | -243.28 | -314.43 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.46 | 6.22 | 0.14 | 0.29 | 0.23 | Upgrade
|
| Sale (Purchase) of Intangibles | -4.95 | -8.56 | -16.29 | -6.76 | -6.89 | Upgrade
|
| Investment in Securities | -1,154 | - | 51.13 | - | 261.51 | Upgrade
|
| Other Investing Activities | -2.39 | -10.87 | 0.16 | -3.87 | -10.41 | Upgrade
|
| Investing Cash Flow | -1,451 | -293.38 | -233.29 | -253.62 | -69.98 | Upgrade
|
| Short-Term Debt Issued | 141.37 | 35.33 | 63.47 | 77.22 | - | Upgrade
|
| Total Debt Issued | 141.37 | 35.33 | 63.47 | 77.22 | - | Upgrade
|
| Short-Term Debt Repaid | -50.04 | -33.16 | -107.47 | - | -9.49 | Upgrade
|
| Long-Term Debt Repaid | -15.98 | -12.47 | -11.29 | -11.19 | -10.26 | Upgrade
|
| Total Debt Repaid | -66.02 | -45.63 | -118.76 | -11.19 | -19.75 | Upgrade
|
| Net Debt Issued (Repaid) | 75.35 | -10.3 | -55.29 | 66.03 | -19.75 | Upgrade
|
| Common Dividends Paid | -276.76 | -237.22 | -284.67 | -379.56 | -395.37 | Upgrade
|
| Other Financing Activities | -0.89 | 2.64 | -1.03 | -1.3 | 2.35 | Upgrade
|
| Financing Cash Flow | -202.3 | -244.89 | -340.98 | -314.83 | -412.77 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1.97 | 11.82 | -10.04 | 8.44 | -1.1 | Upgrade
|
| Net Cash Flow | -1,056 | 224.46 | -353.19 | 213.79 | 25.97 | Upgrade
|
| Free Cash Flow | 304.62 | 470.74 | -37.3 | 530.51 | 195.4 | Upgrade
|
| Free Cash Flow Growth | -35.29% | - | - | 171.50% | -74.50% | Upgrade
|
| Free Cash Flow Margin | 9.63% | 13.82% | -1.17% | 16.25% | 7.07% | Upgrade
|
| Free Cash Flow Per Share | 0.38 | 0.59 | -0.05 | 0.67 | 0.25 | Upgrade
|
| Cash Interest Paid | - | 8.07 | 9.16 | 7.89 | 6.55 | Upgrade
|
| Cash Income Tax Paid | - | 105.6 | 103.42 | 77.51 | 57.98 | Upgrade
|
| Levered Free Cash Flow | 187.41 | 424.85 | -74 | 465.34 | 91.58 | Upgrade
|
| Unlevered Free Cash Flow | 193.58 | 429.9 | -68.29 | 470.29 | 95.68 | Upgrade
|
| Change in Working Capital | -84.58 | -41.75 | -489.07 | -24.36 | -94.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.